| 000 | 01497 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516145310.0 | ||
| 264 | 0 | _c20140122 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1536-4844 | ||
| 024 | 7 |
_a10.1097/MIB.0b013e318281f362 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThin, Lena W Y | |
| 245 | 0 | 0 |
_aOral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. _h[electronic resource] |
| 260 |
_bInflammatory bowel diseases _cJun 2013 |
||
| 300 |
_a1490-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 |
_aDrug Resistance _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTacrolimus _xtherapeutic use |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMurray, Kevin | |
| 700 | 1 | _aLawrance, Ian C | |
| 773 | 0 |
_tInflammatory bowel diseases _gvol. 19 _gno. 7 _gp. 1490-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MIB.0b013e318281f362 _zAvailable from publisher's website |
| 999 |
_c22697603 _d22697603 |
||